Non‐targeted proteomics was performed on muscle biopsy samples taken pre‐ and post‐intervention. Samples preparation is described in Supplementary Information 6. Samples were analyzed using liquid chromatography‐coupled mass spectrometry. Peptides were separated on an EASY‐Spray column ES803 and analyzed on a Dionex UltiMateTM 3000 UHPLC system and an Orbitrap FusionTM LumosTM platform (both Thermo Fisher Scientific). (Davis et al., 2017 (link)) Raw data were imported into Progenesis QI (Waters, UK) using default parameters. Tandem mass spectrometry data were searched using Mascot (v.2.5, Matrix Science) against the Universal Periodic Review human database. Mass tolerances were set to 10 ppm for precursor and 0.5 Da for fragment masses. Peptide‐level false discovery rate was adjusted to 1%. Peptides with a score of <20 were discarded. Data were cantered and normalized in Progenesis QI (Waters), before being extracted for further data processing in Perseus (Max‐Plank Institute of Biochemistry) (Tyanova & Cox, 2018 (link)).
Free full text: Click here